Targeting HCK in Pancreatic Ductal Adenocarcinoma to Restrict Tumour Growth and Metastasis

靶向胰腺导管腺癌中的 HCK 来限制肿瘤生长和转移

• 批准号: nhmrc : GNT1166447
• 负责人: Dr Ashleigh Poh
• 金额: $ 32.72万
• 依托单位: La Trobe University
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-hck-pancreatic-growth-metastasis/1349391
• 关键词: Targeting; HCK; Pancreatic; Ductal; Adenocarcinoma

This project will define the therapeutic benefit of targeting a protein known as Haematopoietic Cell Kinase (HCK) in pancreatic ductal adenocarcinoma. Increased HCK activity promotes tumour growth by facilitating the polarisation of macrophages towards an alternatively activated “tumourigenic” endotype, which are a major component of pancreatic tumours. We hypothesise that the therapeutic targeting of HCK will reduce pancreatic tumour growth by impairing alternative macrophage polarisation.

该项目将确定靶向胰腺导管腺癌中称为造血细胞激酶（HCK）的蛋白质的治疗益处。增加的HCK活性通过促进巨噬细胞朝向替代性活化的“致瘤”内型极化来促进肿瘤生长，所述内型是胰腺肿瘤的主要组分。我们假设HCK的治疗靶向将通过损害替代巨噬细胞极化来减少胰腺肿瘤生长。